Moist exposed burn ointment effectiveness for capecitabine associated grade ii and iii hand foot syndrome on stage iii colonic

Abstract

BACKGROUND: Hand-foot syndrome (HFS), also known as palmoplantar erythrodysesthesia, is a common adverse effect of the fluoropyrimidine chemotherapy agent capecitabine. HFS of any grade is reported to affect 43–71% of patients treated with single-agent capecitabine chemotherapy. Although not life-threatening, it can have adverse effects on the quality of life and daily living activities of a patient. Sometimes the dose interruptions and reductions required after observation of HFS can also impact on dose intensity and treatment outcomes. AIM: As an option for the treatment of this case, we would report our preliminary study of the effectiveness of moist exposed burn ointment (MEBO) for stage II and III HFS. METHODS: We will evaluate the clinical sign and symptoms of HFS Grade II and III associated with capecitabine as adjuvant chemotherapy agent on locally advanced stage colonic adenocarcinoma. All patients with HFS will treated with topical MEBO twice daily, the clinical improvement of the symptoms will be recorded. RESULTS: We reported eight cases of Grade II and III HFS, two patients were Grade III HFS and the others were Grade II. These symptoms occurred after 2 until 3 months after capecitabine administration for locally advanced (stage III) colonic adenocarcinoma. Topical MEBO was used twice a day for 3 months, pain reduction was achieved with no capecitabine dose interruption and reduction during the chemotherapy period. Allergic reaction was not found during and after MEBO application in this case. CONCLUSION: MEBO was an effective treatment option in managing hand-foot syndrome, better option in reducing the pain without interrupting the capecitabine doses.